Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1998-06-12
2000-06-27
Gitomer, Ralph
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
514141, 514185, 514700, A61K 31335, A61K 3133, A61K 3166
Patent
active
060807792
ABSTRACT:
Compounds of the formula ##STR1## wherein X in each of formulas (1) and (2) represents a substituted or unsubstituted alkylene, alkenylene, or alkynylene linker of 2-6 C;
Y represents one or more carbocyclic or heterocyclic rings; when two or more rings are present in Y, they may optionally be fused; and
R' represents a cation, H or a substituted or unsubstituted alkyl group of 1-6 C; and
the dotted lines represent optional .pi.-bonds,
promote bone formation and are thus useful in treating osteoporosis, bone fracture or deficiency, primary or secondary hyperparathyroidism, periodontal disease or defect, metastatic bone disease, osteolytic bone disease, post-plastic surgery, post-prosthetic joint surgery, and post-dental implantation. These compounds can be used in combination with other bone growth-promoting compounds and/or estrogens and/or bisphosphonates for this purpose.
REFERENCES:
patent: 5258376 (1993-11-01), Bernstein
patent: 5280040 (1994-01-01), Labroo et al.
patent: 5462932 (1995-10-01), Brenner et al.
patent: 5545661 (1996-08-01), Cullinan
patent: 5604257 (1997-02-01), Tabe et al.
Wozney, J.M., "The Bone Morphogenetic Protein Family and Osteogenesis," Molecular Reproduction and Development 32:160-167 (Jun. 1992).
Harris, S.E., et al., "Effects of Transforming Growth Factor .beta. on Bone Nodule Formation and Expression of Bone Morphogenetic Protein 2, Osteocalcin, Osteopontin, Alkaline Phosphatase, and Type I Collagen mRNA in Long-Term Cultures of Fetal Rat Calvarial Osteoblasts," Journal of Bone Mineral Research 9(6):855-863 (Jun. 1994).
Luckman, S.P. et al. , J.Bone Min Res (1998) 13:581-589.
Wang, G-J., et al., "Lipid Clearing Agents in Steroid-induced Osteoporosis," J Formos Med Assoc 94(10):589-592 (Oct. 1995).
Cui, Q., et al., "Lovastatin Prevents Steroid-Induced Adipogenesis and Osteoporosis," Reports of the ASBMR 18.sup.th Annual Meeting (Sep. 1996) Journal of Bone and Mineral Research (Aug. 1996) 11(Supplement 1):S510, p. S217.
Bellows, C.G., et al., "Determination of the Capacity for Proliferation and Differentiation of Osteoprogenitor Cells in the Presence and Absence of Dexamethasone," Developmental Biology 140:132-138 (Jul. 1990).
Rickard, D.J. et al., "Induction of Rapid Osteoblast Differentiation in Rat Bone Marrow Stromal Cell Cultures by Dexamethasone and BMP-2," Developmental Biology (1994) 161:218-228.
Ducy, P., et al., "Increased bone formation in osteocalcin-deficient mice,"Nature (Aug. 1, 1996) 382:448-452.
Baindur Nand
Gasper Shirley R.
Labroo Virender M.
Martinez Theresa
McKernan Patricia A.
Gitomer Ralph
Moran Marjorie A.
Osteoscreen Inc.
ZymoGenetics Corporation
LandOfFree
Compositions and methods for stimulating bone growth does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Compositions and methods for stimulating bone growth, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compositions and methods for stimulating bone growth will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1785162